Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-A11:01 KRAS G12V-specific TCR-T cells
- Development stage
- Unknown
- Lead developer
- Peking University Shenzhen Hospital
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
HLA-A11:01 KRAS G12V-specific TCR-T cells is an autologous T-cell receptor (TCR) engineered T-cell therapy being developed by Peking University Shenzhen Hospital. This cell therapy involves the genetic modification of a patient's own T cells to express a TCR that specifically recognizes the G12V mutation in the KRAS protein when presented by the Human Leukocyte Antigen (HLA) allele A*11:01. KRAS mutations, particularly G12V, are highly prevalent in pancreatic ductal adenocarcinoma (PDAC) and serve as potent neoantigens. By targeting this specific mutation-HLA complex, the TCR-T cells are designed to selectively identify and eliminate tumor cells while sparing healthy tissue. The therapy is currently being evaluated in Phase 1 clinical trials for patients with advanced pancreatic cancer who carry the HLA-A11:01 allele and the KRAS G12V mutation.
- Other names
- HLA-A11:01 restricted KRAS G12V specific TCR-T cellsKRAS G12V-specific TCR-T cellsHLA-A11:01 KRAS G12V TCR-T
02
Targets
KRASG12V (KRAS G12V)KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)
Beyond the preview
Go deeper on HLA-A11:01 KRAS G12V-specific TCR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-A11:01 KRAS G12V-specific TCR-T cells.